Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2007 Mar;7(3):319-30.

Monoclonal antibody-based therapeutics for leukemia.

Author information

1
Experimental Therapeutics, ImClone Systems, 180 Varick Street, New York, NY 10014, USA. yiwen.li@imclone.com

Abstract

Monoclonal antibodies (mAbs) represent a unique class of therapeutics because of their exquisite antigen specificity and effector mechanisms. Clinically, antibody-based therapy has increasingly become an established modality for the treatment of cancer. Among the nine mAbs and immunoconjugates approved by the FDA for therapeutic indications in oncological diseases, five are for use in hematological malignancies. Alemtuzumab is approved for B cell chronic lymphocytic leukemia; rituximab, an anti-CD20 antibody approved for the treatment of B cell non-Hodgkin's lymphoma, is being tested in patients with chronic lymphocytic leukemia; and gemtuzumab ozogamicin is marketed for relapsed acute myelogenous leukemia in patients of > 60 years of age. A number of other mAbs are in different stages of clinical development for antileukemia therapy. This article discusses the general aspects and mechanisms of action of therapeutic mAbs, and highlights the development of antibody-based therapies in leukemia.

PMID:
17309324
DOI:
10.1517/14712598.7.3.319
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center